Nitin V. Sheth, Ph.D.
President & CEO, Indicus Pharma
Nitin Sheth, Ph.D., is a President
& CEO of Indicus Pharma and one of the founding members
of a startup organization. Dr. Sheth has twenty years of progressive
leadership experience in Pharmaceutical Research and Development
organization to carry out product development, process & validation
activities and global product development & technology transfer
activities. During these years, he had successfully developed immediate
as well as controlled release products that resulted in approximately
90+ ANDA submissions (includes P-IV & first to file submissions).
Dr. Sheth is specialized in the development of oral controlled release
products and received number of worldwide formulation patents on
CR product development. He is knowledgeable in US FDA requirements
of ANDA submissions and US generic market dynamics.
to founding this company, Dr. Sheth served as Vice President, Research
& Development for Eon Labs from April 2002 to January 2005 where
he was responsible for entire R & D efforts of Eon Labs. Dr.
Sheth served as Director, Product Development for Ivax Pharmaceuticals,
Inc. from March 1998 to April 2002 where he was responsible for
developing generic products. From September 1993 to March 1998,
he was Manager, Product Development for Zenith Labs and later named
as Zenith Goldline Pharmaceuticals, Inc. (a wholly owned subsidiary
of IVAX Corporation). Dr. Sheth held positions with American Cynamid
Co. in Formulations Research Division from June 1986 to August 1993,
including Group Leader of Formulation Development, where he was
responsible for research and development activities on new as well
as marketed products. Dr. Sheth received his B.S. degree in Pharmacy
from University of Bombay and M.S. degree in Pharmaceutics from
Gujarat University in India. Dr. Sheth received his Ph.D. in Pharmaceutics
from University of Pacific, California. From 1983 to 1986, Dr. Sheth
worked as a postdoctoral research fellow at University of Utah under
Dr. Higuchi & Dr. Spruance on Topical Delivery of Antivirals.